Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo.

Metsera’s GLP-1 peptide has a long half-life, meaning it could be administered once a month. And the company is ready to scale up. Published: Feb. 25, 2025 at 1:42 p.m. ET. Share.

Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose weight in a small, early-stage trial, showing potential for ...